Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study

Open access
Serruys, Patrick W., Emanuelsson, Håkan, van der Giessen, Wim, Lunn, Anthony C., Kiemeney, Ferdinand, Macaya, Carlos, Rutsch, Wolfgang, Heyndrickx, Guy, Suryapranata, Harry, Legrand, Victor, Goy, Jean Jacques, Materne, Pierre, Bonnier, Hans, Morice, Marie-Claude, Fajadet, Jean, Belardi, Jorge, Colombo, Antonio, Garcia, Eulogio, Ruygrok, Peter, de Jaegere, Peter, Morel, Marie-Angèle·1996·Circulation

Abstract

Background The purpose of the Benestent-II Pilot Study was to evaluate the safety of delaying and eliminating anticoagulant therapy in patients receiving a heparin-coated stent in conjunction with antiplatelet drugs. Methods and Results The study consisted of three initial phases (I, II, III) during which resumption of heparin therapy after sheath removal was progressively deferred by 6, 12, and 36 hours. In phase IV, coumadin and heparin were replaced by 250 mg ticlopidine and 100 mg aspirin. Of the 207 patients with stable angina pectoris and a de novo lesion in whom heparin-coated stent implantation was attempted, implantation was successful in 202 patients (98%). Stent thrombosis did not occur during all four phases, and the overall clinical success rate at discharge was 99%. Bleeding complications requiring blood transfusion or surgery fell from 7.9% in phase I to 5.9%, 4%, and 0% in the three following phases. Hospital stay was 7.4, 6.1, 7.2, and 3.1 days for the consecutive phases. The restenosis rate for the combined four phases was 13% (15% in phase I, 20% in phase II, 11% in phase III, and 6% in phase IV). The overall rate of reintervention for the four phases was 8.9%. At 6 months, 84%, 75%, 94%, and 92% of the patients of phases I to IV, respectively, were event free. For the four phases, the event-free rate was 86%, which compares favorably with the rate observed in the Benestent-I study (80%; relative risk, 0.68 [0.45 to 1.04]). Conclusions The implantation of stents coated with polyamine and end-point–attached heparin in stable patients with one significant de novo coronary lesion is well tolerated, is associated with no (sub)acute stent thrombosis, and results in a favorable event-free survival after 6 months.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.93.3.412

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 408

Metadata

Authors
Serruys, P. W., Emanuelsson, H., van der Giessen, W., Lunn, A. C., Kiemeney, F., Macaya, C., Rutsch, W., Heyndrickx, G., Suryapranata, H., Legrand, V., Goy, J. J., Materne, P., Bonnier, H., Morice, M.-C., Fajadet, J., Belardi, J., Colombo, A., Garcia, E., Ruygrok, P., de Jaegere, P., & Morel, M.-A.
Venue
Circulation
Published
1996-02
Volume
93
Issue
3
Pages
412-422
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2140150910
Cited by
408
References
21
FWCI
88.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study. https://app.cochat.ai/papers/10.1161/01.cir.93.3.412
The paper
Serruys, P. W., Emanuelsson, H., van der Giessen, W., Lunn, A. C., Kiemeney, F., Macaya, C., Rutsch, W., Heyndrickx, G., Suryapranata, H., Legrand, V., Goy, J. J., Materne, P., Bonnier, H., Morice, M.-C., Fajadet, J., Belardi, J., Colombo, A., Garcia, E., Ruygrok, P., . . . Morel, M.-A. (1996). Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study. Circulation. https://doi.org/10.1161/01.cir.93.3.412

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.